Antonino Cattaneo

Biography

Professor Antonino Cattaneo The European Brain Research Institute Rome – The European Brain Research Institute in Rome

Research Interest

In fact, the scientific career of Antonino Cattaneo has followed a parallel track, combining molecular neurobiology together with the development of technologies exploiting recombinant antibodies for protein knock-out (neuroantibodies and intrabodies), with a particular focus on CNS applications. In this field, Cattaneo has pioneered and developed the neuroantibody strategy, whereby the expression of recombinant antibodies in the CNS is used to interfere with neuronal functions, creating experimental models  for mechanistic studies. In further developments, Cattaneo has developed the targeting and use of intracellular antibodies (intrabodies) to achieve protein knock-out in different subcellular compartments. This has allowed to develop transgenic models, based on the expression of recombinant antibodies to NGF in the brain of adult transgenic mice, and to demonstrate that interfering with the function of NGF in the adult Central Nervous System leads to a progressive neurodegenerative phenotype that recapitulates in a comprehensive way most of the major hallmarks of Alzheimer’s Disease (AD). This work allowed to extend our understanding of the role of NGF in the CNS and to link the signalling of NGF and of its precursor form proNGF to phenotypic endpoints relevant for Alzheimer’s disease (AD). This led to formulate the hypothesis of “too little NGF-too much proNGF” as a new framework for the study of Alzheimer’s disease pathological mechanisms. Since, in a therapeutical perspective, NGF needs to be locally delivered to the CNS, in order to avoid conflicting undesired effects  by NGF on  peripheral targets, Cattaneo has exploited and developed an intranasal delivery route for the access of NGF to the brain, obtaining conclusive proof of principle evidence for the ability of olfactory delivered NGF to rescue neurodegeneration in animal models. He is currently developing, as a potential therapeutic for Alzheimer´s Disease, "painless NGF", a variant of NGF optimized to remove the pain sensitizing activity of NGF, that has limited its therapeutical applications sofar. Two humanized antibodies developed by Cattaneo are currently undergoing clinical development by industrial partners.